Aggregator

针对精神分裂症患者及其家人的干预措施是否比标准治疗更有效?

8 months ago
针对精神分裂症患者及其家人的干预措施是否比标准治疗更有效? 关键信息 • 家庭干预可能会减少精神分裂症患者的复发。 • 家庭干预可能会减轻照顾者的负担,并可能改善精神分裂症患者家庭成员的情感表达(即不利的家庭环境,包括家庭关系和互动模式)。 • 需要更多的研究来得出关于家庭干预对精神分裂症患者及其家庭应用效果的有力结论。 什么是精神分裂症?它对家庭有何影响? 精神分裂症是一种严重的、长期存在的精神障碍。精神分裂症患者可能出现妄想、幻觉、言语紊乱、功能下降和自我护理能力下降,或这些症状的组合。他们经常康复后又再次发病(复发)。治疗通常是长期的,包括药物治疗和“社会心理”干预,如社交技能训练、谈话和行为疗法,帮助患者康复和控制他们的症状。家庭在照顾生病的亲属方面发挥着关键作用,这反过来可能会给家庭带来较高的心理压力和负担,进而可能增加患者复发的风险。家庭干预注重改善家庭的知识、情感、行为和整体家庭环境,从而有利于家庭幸福和患者症状的管理。尽管担心隐私和给家人带来负担,大多数精神分裂症患者还是同意让家人参与他们的照护。 我们想要了解什么? 尽管一些指南推荐家庭干预,但目前关于这些措施对精神分裂症患者及其家庭有效性的证据尚不一致且尚未完全确定。我们的目的是评估与标准治疗相比,基于家庭的干预对精神分裂症或精神分裂症样精神障碍的患者及其家庭的效果。 我们做了什么? 我们检索了对精神分裂症患者...

心理或教育干预(或两种结合)能否减少居家老年人跌倒的发生?

8 months ago
心理或教育干预(或两种结合)能否减少居家老年人跌倒的发生? 关键信息 – 心理干预(包括动机访谈(一种旨在解决不确定性和鼓励个人承诺来改变行为的方法)和指导)结合定制教育(例如,给予运动或药物建议)对减少跌倒人数(跌倒者)的效果很小,但可能会减少人们跌倒的次数(尽管尚不清楚减少多少)。 - 没有足够高质量的证据来确信个人心理或教育干预的效果。 我们想了解什么? 随着年龄的增长,我们更容易跌倒,并有可能伤到自己。据估计,每年有三分之一的老年人会跌倒,这会影响他们的独立性和健康寿命。跌倒的原因有很多,针对不同风险因素(如肌肉无力、视力、环境或药物)定制的锻炼和干预措施可以减少跌倒。如果我们担心跌倒,我们就可能会减少活动,这可能会增加跌倒的风险。心理干预旨在减少对跌倒的担忧、提高认识或提高采取行动预防跌倒的动力。教育旨在让人们了解如何减少跌倒的风险。我们想研究心理或教育干预(或两者结合)是否有助于减少在家中居住的老年人跌倒的发生。 我们做了什么? 我们检索了将以下干预措施与居家老年人常规治疗进行对比的研究。 – 认知行为疗法(一种谈话疗法,可以通过改变人们的思维和行为方式来帮助人们解决问题)。 – 动机访谈(一种通过观察一个人的疑虑并鼓励个人承诺来提高他改善行为的动力的方法)。 – 其他心理干预,例如引导意象疗法(一种教导人们运用想象力来降低负面情绪的技术)或指导。 – 教育(针对个人...

无创正压通气治疗儿童急性哮喘

8 months 1 week ago
无创正压通气治疗儿童急性哮喘 关键信息 没有一项试验报告有任何死亡或严重的不良影响(除了一项试验报告了插管率(将管子插入气管))。 无创正压通气可能改善哮喘症状评分,降低插管率,并略微缩短儿科重症监护病房的住院时间,但结果非常不确定。 如何治疗儿童急性哮喘? 哮喘是世界范围内的一个重大公共卫生问题,具有重大的经济影响。患有哮喘的儿童经常会因哮喘急性发作而住院,有时甚至需要住进重症监护室。 对急性哮喘发作的治疗,特别是对住进重症监护病房的儿童,主要包括吸入或静脉注射(通过静脉给予)支气管扩张剂,以放松气道肌肉和皮质类固醇,以减少炎症。对于许多此类患者来说,呼吸是困难的,因此需要通过无创正压通气(NPPV),如持续气道正压通气(CPAP)或双水平气道正压通气(BiPAP)来帮助呼吸。这两种方法都可以在不使用侵入性人工气道的情况下提供正压支持。CPAP在呼吸周期中向患者提供恒定的压力,而BiPAP在吸气时比呼气时提供更高的压力。这种正压通常透过鼻导管或全面罩(覆盖鼻子及嘴巴)连接流量生成器来传递。 我们想要了解什么? 虽然 NPPV 可作为急性哮喘常规治疗的一种附加疗法,但临床指南并不推荐这样做,因此我们希望开展本综述。由于NPPV在急性哮喘儿童中的使用增加,我们决定更新之前的综述。 我们做了什么? 我们评价了NPPV的现有证据,以评估其对急性哮喘儿童的益处和伤害。 我们发现了什么? ...

Water fluoridation less effective now than in past

8 months 1 week ago

An updated Cochrane review has found that the dental health benefits of adding fluoride to drinking water may be smaller now than before fluoride toothpaste was widely available. 

The team of researchers from the Universities of Manchester, Dundee and Aberdeen reviewed the evidence from 157 studies which compared communities that had fluoride added to their water supplies with communities that had no additional fluoride in their water. They found that the benefit of fluoridation has declined since the 1970s, when fluoride toothpaste became more widely available. 

The contemporary studies were conducted in high-income countries. The impact of community water fluoridation in low- and middle-income countries is less clear, due to the absence of recent research.  

Fluoride, used in many commercially available toothpastes and varnishes, is known to reduce tooth decay. Governments in many countries have added fluoride to the drinking water supply to improve population oral health, although there are polarized views on whether this is the right action to take.  

“When interpreting the evidence, it is important to think about the wider context and how society and health have changed over time,” says co-author Anne-Marie Glenny, Professor of Health Sciences Research at the University of Manchester. “Most of the studies on water fluoridation are over 50 years old, before the availability of fluoride toothpaste. Contemporary studies give us a more relevant picture of what the benefits are now.”  

Results from studies conducted after 1975 suggest that the initiation of water fluoridation schemes may lead to slightly less tooth decay in children’s baby teeth. Analysis of these studies, covering a total of 2,908 children in the UK and Australia, estimates that fluoridation may lead to an average of 0.24 fewer decayed baby teeth per child. However, the estimate of effect comes with uncertainty, meaning it’s possible that the more recent schemes have no benefit. By comparison, an analysis of studies with 5,708 children conducted in 1975 or earlier estimated that fluoridation reduced the number of decayed baby teeth, on average by 2.1 per child.  

The same contemporary studies (conducted after 1975) also looked at the number of children with no decay in their baby teeth. The analysis found that fluoridation may increase the number of children with no tooth decay by 3 percentage points, again with the possibility of no benefit. 

The review was only able to draw conclusions about the impact on children’s teeth, with similar findings across both baby and permanent teeth. There were no studies with adults that met the review’s criteria.  

“The evidence suggests that water fluoridation may slightly reduce tooth decay in children,” says co-author Dr Lucy O’Malley, Senior Lecturer in Health Services Research at the University of Manchester. “Given that the benefit has reduced over time, before introducing a new fluoridation scheme, careful thought needs to be given to costs, acceptability, feasibility and ongoing monitoring.” 

Advocates have suggested that one of the key benefits of water fluoridation is that it reduces oral health inequalities. This updated review sought to examine this question and did not find enough evidence to support this claim, although this doesn’t necessarily mean there is no effect. 

The review’s findings accord with recent observational studies including the LOTUS study, which compared anonymised dental health records with water fluoridation status for 6.4 million adults and adolescents in England between 2010 and 2020. People in fluoridated areas needed slightly fewer invasive dental treatments with no significant impact on inequalities. 

“Contemporary evidence using different research methodologies suggest that the benefits of fluoridating water have declined in recent decades,” says Tanya Walsh, Professor of Healthcare Evaluation at the University of Manchester, co-author on both the Cochrane review and the LOTUS study. “Oral health inequalities are an urgent public health issue that demands action. Water fluoridation is only one option and not necessarily the most appropriate for all populations.” 

“Whilst water fluoridation can lead to small improvements in oral health, it does not address the underlying issues such as high sugar consumption and inadequate oral health behaviours,” says co-author Janet Clarkson, Professor of Clinical Effectiveness, University of Dundee. “It is likely that any oral health preventive programme needs to take a multi-faceted, multi-agency approach.” 

Iheozor-Ejiofor Z, Walsh T, Lewis SR, Riley P, Boyers D, Clarkson JE, Worthington HV, Glenny A-M, O'Malley L. Water fluoridation for the prevention of dental caries. Cochrane Database of Systematic Reviews TBD, Issue TBD. Art. No.: CD010856. DOI: 10.1002/14651858.CD010856.pub3.

 

Friday, October 4, 2024
Mia Parkinson

预防艾滋病毒阳性孕妇感染疟疾的药物

8 months 1 week ago
预防艾滋病毒阳性孕妇感染疟疾的药物 关键信息 ·对于艾滋病毒抗体阳性的孕妇,在艾滋病毒感染者的常规感染预防治疗(每日复方新诺明)中添加抗疟药物(如甲氟喹或双氢青蒿素/哌喹): -可能减少母亲分娩时感染疟疾的风险; -可能减少胎盘中的疟疾感染; -可能不会影响产前或产后失去婴儿的风险,也不会影响婴儿出生体重过低的风险。 ·虽然甲氟喹与每日复方新诺明合用可能会降低艾滋病毒阳性妇女感染疟疾的风险,但它可能会增加艾滋病毒母婴传播的风险,并可能有较高的药物不良反应风险。 ·双氢青蒿素/哌喹添加到每天服用复方新诺明中,可能会降低艾滋病毒阳性孕妇胎盘感染疟疾的风险。它可能对低出生体重或出生前后失去婴儿的风险,或轻微副作用(如呕吐)的风险可能没有影响。 为什么艾滋病毒阳性孕妇的疟疾预防很重要? 艾滋病毒抗体阳性的孕妇容易感染疟疾。同时感染疟疾和艾滋病毒会怀孕期间的疟疾恶化,从而增加妇女及其婴儿患健康并发症的风险。在疟疾常见的许多国家,建议每天服用一种名为复方新诺明的药物,以预防艾滋病毒感染者(包括孕妇)的感染。服用复方新诺明的妇女不能服用建议用于预防妊娠期疟疾的药物磺胺多辛-乙胺嘧啶,因为这两种药物之间可能存在负相互作用。 我们想了解什么? 我们想知道目前可用的抗疟药物在用于预防艾滋病毒阳性孕妇的疟疾是否有效和安全。这是对2011年发表的Cochrane系统综述的更新。 我们做了什么? 我们检索...

体感游戏对痴呆或轻度认知障碍患者的益处与风险?

8 months 2 weeks ago
体感游戏对痴呆或轻度认知障碍患者的益处与风险? 关键信息 • 参与纳入身体活动的视频游戏(“体感游戏”)可能有助于痴呆和轻度认知障碍患者改善学习和记忆等思维技能,但我们并不确定。 • 目前几乎没有证据表明体感游戏能改善痴呆和轻度认知障碍患者的行走能力、平衡能力或处理日常任务(如结账或购物)的能力。 什么是痴呆和轻度认知障碍? 痴呆是一种脑部变化影响个人记忆、思维和执行日常事务能力的病症。它可能导致人们在记住事情、制定计划、集中注意力或沟通方面遇到困难。这些变化通常会随着时间的推移而加重,最终可能干扰日常生活。 轻度认知障碍是在记忆和思维方面存在一些困难,但尚未达到痴呆的程度。然而,轻度认知障碍可能会增加进展为痴呆的风险。尽管轻度认知障碍患者可能在清晰地记忆或思考方面存在困难,但他们仍然能够处理日常任务,如结账、购物和保持家中整洁。简而言之,轻度认知障碍存在一些记忆和思维上的困难,但没有痴呆那么严重,但是可能随着时间的推移而恶化。 什么是体感游戏? 目前,减缓痴呆等疾病的治疗方法并不多。但我们知道,终生保持身体和心理活跃可以降低患痴呆的风险。一些专家认为,鼓励保持身体和心理活跃可能有助于减轻痴呆症状和轻度认知障碍的影响。随着新技术的发展,我们现在可以利用虚拟现实和互动游戏(称为体感游戏)提供身体和心理训练。体感游戏被视为一种良好的选择,因为它们相对容易让老年人在家中使用,并且能够提...

Cochrane welcomes global commitment to evidence synthesis

8 months 2 weeks ago

At the United Nations Summit of the Future, two major funding bodies announced £54.2 million of new funding for evidence synthesis: £45 million from Wellcome and £9.2 million from UK Research and Innovation (UKRI).

The announcements represent significant investment in evidence synthesis to help tackle global inequity and address the UN’s Sustainable Development Goals. Cochrane was represented at the summit by our Editor in Chief, Dr Karla Soares-Weiser.

“It is invigorating to see major global funders recognizing the importance of evidence synthesis in addressing the challenges facing the world today and in the future,” says Karla. “This significant investment has the potential to catalyze a step change in evidence synthesis, making it more timely, relevant and equitable. Cochrane has a proud history of advancing evidence synthesis, and we stand ready to support this vital global effort. I am especially excited at the potential to reduce global inequities in both producing and accessing high-quality evidence.”

Both funding calls are aimed at building infrastructure to support rapid evidence synthesis projects so that policymakers have access to the latest evidence on a given topic. The Wellcome announcement focuses on ‘living evidence synthesis’, where systematic reviews are continually updated so they always reflect the latest evidence. Wellcome’s announcement notes that ‘the Cochrane Collaboration, which produces gold-standard evidence syntheses in medicine, increasingly backs living evidence models’.

Living evidence

Cochrane is a pioneer of living systematic reviews, having published the world’s first living systematic reviews in 2017. Lessons from the pilot project were published in 2019, in a project co-led by Professor Tari Turner at Cochrane Australia, who serves on Cochrane’s Editorial Board and is Academic Director of the Australian Living Evidence Collaboration.

“It’s fantastic to see this global commitment to living evidence and recognition of Cochrane's leadership in this area,” says Tari. “The new funding is fantastic news for both evidence synthesis professionals and decision-makers who need up-to-date evidence. Living reviews come with many opportunities and challenges which we identified in our pilot programmes, and it’s great to see them getting the attention they deserve.”

 

Tuesday, September 24, 2024
Harry Dayantis

Cochrane’s pioneering role in living evidence

8 months 2 weeks ago

As the pace of new research accelerates, keeping systematic reviews up-to-date with the latest evidence has become increasingly vital. Cochrane is at the forefront of this evolution with our leadership in living systematic reviews (LSRs)—a dynamic approach that ensures evidence remains current and relevant.

What's a systematic review?
A systematic review attempts to identify, appraise, and synthesize all the empirical evidence that meets pre-specified eligibility criteria to answer a specific research question. Researchers conducting systematic reviews use explicit, systematic methods that are selected with a view aimed at minimizing bias, to produce more reliable findings to inform decision making. 

For those new to the concept, here's a short video from Cochrane Consumers and Communication that explains what a systematic review is, how researchers prepare them, and why they’re a crucial part of making informed health decisions  - both for professionals and the public.

What is living evidence?
Living evidence refers to a systematic review that is continually updated to incorporate new and relevant information as it becomes available. Unlike traditional systematic reviews, which may be updated infrequently or not at all, living systematic reviews (LSRs) are underpinned by ongoing, active monitoring of the evidence base.

Key Features of LSRs:

  • Continual Monitoring: LSRs involve regular, often monthly, searches for new evidence.
  • Immediate Updates: New important evidence, including data, studies, or information, is promptly included.
  • Up-to-Date Communication: The status of the review and any new evidence are communicated clearly and regularly.

While LSRs employ the same core review methods as other Cochrane Reviews, they also incorporate predefined and transparent decisions on how frequently new evidence is sought, how it is integrated, and the rationale behind these decisions. Cochrane continues to innovate by providing updated information on the status of our reviews and each updated review is assigned a new citation and DOI, linking it to previous versions and ensuring the most current evidence is available.



Watch all the videos from this series

Why living systematic reviews?

LSRs represent a significant advancement in evidence synthesis, connecting evidence and practice more seamlessly than traditional methods. They are hugely valuable to healthcare professionals, decision-makers, guideline developers,  policy-makers, funders, consumers (patients and carers), and publishers who require up-to-date evidence for informed decision-making.

Technological advancements, such as online platforms, linked data, and machine learning, have made large-scale living evidence approaches feasible. The growth of collaborative research, open data initiatives, and citizen science also supports the maintenance of high-value datasets and LSRs - areas that Cochrane is also leading.

Cochrane’s role and innovations

Since launching the world's first pilot living reviews in 2017, Cochrane has been a trailblazer in this field. Professor Tari Turner, member of the Cochrane Library Editorial Board and Director of the Australian Living Evidence Collaboration based at  Cochrane Australia, has been instrumental in developing and applying living evidence approaches. According to Tari:

"Living evidence synthesis is transforming how we navigate uncertainty and make evidence accessible. By continually updating our living reviews, Cochrane is ensuring that decision-makers have the most current information at their fingertips."

Living systematic reviews are a testament to Cochrane's commitment to producing evidence that is not only trustworthy but also continuously relevant. As we move forward, we remain dedicated to leading in this space and advancing the field of evidence synthesis.

Monday, October 28, 2024
Muriah Umoquit

辅助技术能否帮助改善成人中风后因肌肉和肌腱缩短而导致的关节僵硬?

8 months 2 weeks ago
辅助技术能否帮助改善成人中风后因肌肉和肌腱缩短而导致的关节僵硬? 关键信息 •由于我们只发现了7项低质量的研究,因此我们无法确定使用辅助技术治疗是否优于传统治疗。 •需要进一步来衡量研究辅助技术治疗成年中风患者挛缩的利弊。 什么是挛缩? 中风后,许多人会因肌肉和肌腱变短和变硬而导致肢体畸形。挛缩的主要原因是肢体被固定在缩短的位置。 什么是辅助技术? 辅助技术是使用电流或机械手段(如夹板)拉伸肌肉和软组织的设备。 我们想了解什么? 我们想知道是否有任何辅助技术比常规治疗、不治疗或其他辅助技术更好的改善成人中风后的被动活动范围(一个人在外界帮助下关节活动的程度)和卫生状况。我们还想了解辅助技术是否会产生任何不良影响。 我们做了什么? 我们检索了评估辅助技术与无治疗、常规治疗或其他辅助技术相比效果的研究。我们对研究结果进行了比较和总结,并根据研究方法和规模等因素对证据的可信度进行了评级。 我们发现了什么? 我们发现有7项对辅助技术和常规疗法进行了比较的小型研究。辅助技术的类型包括电刺激、夹板、使用铰链板定位手腕以及带有电刺激的非机器人装置。治疗时间持续了4至12周。一些研究将中风以外的患者和中风患者都包括在内。在可能的情况下,我们只分析了中风患者的结果。 主要研究结果 我们仅分析了五项涉及252人研究的数据。治疗的即时效果是在研究期间最后一次拉伸干预后测量的。 在改善腕部、肩部或肘部被...

对于尚未扩散至身体其他部位的低风险妊娠滋养细胞肿瘤,“保留生育能力”手术有哪些益处和危害?

8 months 2 weeks ago
对于尚未扩散至身体其他部位的低风险妊娠滋养细胞肿瘤,“保留生育能力”手术有哪些益处和危害? 关键信息 我们对不影响生育功能的手术(即“保留生育功能”的手术干预)在伴随或不伴随化疗情况下治疗低风险、未扩散到身体其他部位的妊娠滋养细胞肿瘤(即“非转移性”)的益处和风险非常不确定。 需要更大规模、设计良好的研究来确定保留生育功能手术对患有低风险、非转移性妊娠滋养细胞肿瘤女性的益处和伤害。 什么是妊娠滋养细胞肿瘤? 妊娠滋养细胞肿瘤 (Gestational trophoblastic neoplasia ,GTN) 是一种罕见的癌症,可能在怀孕后于子宫内发生,尤其是在葡萄胎妊娠(即受精卵出现异常,导致胎儿和胎盘无法正常发育)后更容易患上。它可能引起异常出血或激素过高。治疗通常根据癌症的严重程度,采用化疗、手术或两者结合的方式进行。化疗是低风险、非转移性妊娠滋养细胞肿瘤患者的标准治疗方法,但这可能会影响女性的生育能力。对于希望保留生育能力的患者,“保留生育能力”手术干预可以作为一种替代方案。接受保留生育能力的手术可以避免化疗带来的副作用。 我们想发现什么? 我们希望了解保留生育能力的手术对治疗成功率、缓解时间、复发、因病死亡、因治疗死亡、怀孕率、生活质量、化疗周期数、任何不良事件以及紧急子宫切除的影响。 我们做了什么? 我们检索了调查保留生育能力手术与化疗的效果比较(比较1)、保留生育能...

治疗贫血的药物是否有助于预防急性肾损伤?

8 months 2 weeks ago
治疗贫血的药物是否有助于预防急性肾损伤? 关键信息 • 当肾脏突然失去过滤血液中废物的能力时,就会发生急性肾损伤。红细胞生成刺激剂主要用于治疗红细胞生成问题,可能对急性肾损伤高风险人群或早期发现的患者有益。 • 对于有发生急性肾损伤风险的人,促红细胞生成刺激剂可能对急性肾损伤的发生风险或死亡风险几乎没有影响,并且可能对启动透析的需求也没有显著影响。同样,肾功能指标和不良事件(如血栓、心脏病发作、中风或高血压)可能也没有差异。 问题是什么? • 当肾脏突然失去过滤血液中废物的能力时,就会发生急性肾损伤。这种情况在需要重症监护的住院患者中最为常见。如果急性肾损伤严重,可能会致命,但对于既往健康的人群,急性肾损伤是可以逆转的。 促红细胞生成刺激剂主要用于治疗红细胞生成问题,通常用于长期肾衰竭(肾脏功能不足以维持生命的状态)的患者。然而,在动物研究中,促红细胞生成刺激剂被证明可帮助保护肾脏免受疾病侵害,因此可能对急性肾损伤高风险人群(如接受心脏手术者)或早期急性肾损伤患者有益。 我们做了什么? 我们检索了所有评估促红细胞生成刺激剂对急性肾损伤高风险人群或急性肾损伤患者的益处和危害的试验。 我们发现了什么? 我们发现了20项研究,共纳入5348名有急性肾损伤风险的人。受试者人数从10到1302不等,所有研究均在医院进行。所有研究均将促红细胞生成刺激剂与安慰剂(假药)或常规护理进行比较。 对...

Cochrane seeks Managing Editor Remote/Flexible

8 months 2 weeks ago

Title: Managing Editor
Specifications: 12 months Fixed Term – Contract
Salary: £42,000 per annum
Location: UK, Germany or Denmark – Remote/Flexible
Closing date: 30 September 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

Cochrane's strength is in its collaborative, global community. We have 110,000+ members and supporters around the world. Though we are spread out across the globe, our shared passion for health evidence unites us. Our Central Executive Team supports this work and is divided into five directorates: Evidence Production and Methods, Publishing and Technology, Development, and Finance and Corporate Services.

Reporting to the Senior Managing Editor and working with members of the Editorial Production and Methods Directorate, the role holder will need to have good awareness of Cochrane guidance for different types of standard and complex systematic reviews (intervention, qualitative, diagnostic test accuracy, prognosis, rapid and overview), plan how they will need to be handled in their team, and work to ensure that deadlines are met. The role holder will also be required to ensure that pilots aimed at innovating the editorial process can be supported as needed.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  • For further information on the role and how to apply, please click here.
  • The deadline to receive your application is 30 September 2024.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Read our Recruitment Privacy Statement
Wednesday, September 18, 2024 Category: Jobs
Lydia Parsonson

Cochrane announces the 2026 Colloquium in India

8 months 3 weeks ago

Cochrane is excited to announce that its flagship event, the Cochrane Colloquium, will be hosted in India in October 2026. Building on the momentum of previous successful gatherings, including the Cochrane London Colloquium and the Global Evidence Summit in Prague, this eagerly awaited event will unite the global healthcare evidence synthesis community to foster collaboration, share insights, and drive lasting impact.

The Cochrane Colloquium is an annual international conference that brings together a diverse range of participants, including researchers, healthcare professionals, policymakers, patients, and carers. It provides a unique platform for those passionate about evidence synthesis and evidence-based healthcare to share knowledge, engage in practical workshops, and explore innovative approaches. The event is also a vibrant space for networking, making it a crucial part of the global effort to improve health outcomes through reliable, high-quality evidence.



The 2026 Colloquium will focus on themes that resonate across healthcare and policy sectors: Bridging Gaps, Global Evidence, Local Impact, and Equitable Action. These themes will drive discussions on the importance of evidence in addressing health disparities and achieving equitable healthcare solutions around the world.

Catherine Spencer, CEO of Cochrane, shared her enthusiasm: “The 2026 Cochrane Colloquium will be pivotal for anyone involved in evidence-based healthcare. These themes are crucial for advancing evidence production, implementation, and policy, and we are excited to develop a programme that addresses these vital areas.”

The Cochrane India Network were at the recent Global Evidence Summit. At their stand they engaged with attendees and provided information about the 2026 Cochrane Colloquium, receiving an enthusiastic response. During the closing plenary, they showcased a video and extended a heartfelt invitation to join them in India for the upcoming Colloquium.

Dr Neeta Mohanty from Cochrane India expressed excitement about hosting the Colloquium."It is an honour to invite you all to India for the 2026 Colloquium. Attending previous Colloquia has been a highlight for our team and we are looking forward to welcoming you and being your warm hosts."

We are excited to put together an engaging programme and to bring the community together. Stay tuned for more updates and sign up for the 2026 Colloquium newsletter to keep in touch and be among the first to receive news and announcements.

Wednesday, September 25, 2024
Muriah Umoquit

颞下颌关节紊乱患者进行咬合治疗的益处和风险是什么?

8 months 3 weeks ago
颞下颌关节紊乱患者进行咬合治疗的益处和风险是什么? 关键信息 对于颞下颌关节紊乱病(temporomandibular disorders,TMD)患者来说,与不接受任何治疗相比,使用一种被称为咬合夹板的护齿器可能会减轻咀嚼时肌肉的疼痛,但结果还很不确定。几乎没有证据表明咬合夹板还能带来其他好处,但这些结果也不确定。 还需要进一步研究,以找到明确的证据证明咬合夹板或咬合调整(即磨牙)是有益还是有害,并评估它们与其他治疗方法相比的效果。 什么是颞下颌关节紊乱病? TMD 会影响下颌关节或移动下颌关节的肌肉,并可能导致疼痛、张口度降低和下颌关节咔嗒声等问题。颞下颌关节紊乱病可能涉及脸部一侧或两侧的肌肉或关节,或两者兼而有之。 什么是咬合治疗? 咬合治疗可以改变上下牙齿咬合面在运动(如咀嚼)或休息时的接触方式。这可以通过佩戴口腔(咬合)夹板来实现,也可以通过调整,即磨牙来实现。根据其作用方式,口夹板可分为稳定型、反射型和复位型。 我们想知道什么? 我们想知道,与不治疗或其他治疗方法相比,咬合治疗对TMD患者的疗效如何。 我们做了什么? 我们检索了研究数据库。我们只选择了随机对照研究,因为这种类型的研究是确保各组受试者相似以及评估治疗是否真正有效的最佳类型。在随机对照研究中,人们被随机分配到一种或另一种治疗方法中,或者分配到不接受任何治疗的组中。理想情况下,这些研究是以 “盲法”进行的,...

对于肾衰竭患者来说,自动化腹膜透析是否优于持续性可移动腹膜透析?

8 months 4 weeks ago
对于肾衰竭患者来说,自动化腹膜透析是否优于持续性可移动腹膜透析? 关键信息 • 肾衰竭患者(即肾脏功能不足以维持生命的情况)需要某种形式的肾脏替代治疗来维持生命。透析的目的是通过清除溶质、毒素和多余液体来模拟正常肾脏的功能。腹膜透析是一种透析方式,它利用腹腔的膜作为过滤器,通过向腹腔内注入溶液来吸收血液中的废物和多余的液体,从而清除体内的代谢废物。我们比较了全自动腹膜透析(通过机器自动输送透析液)与持续性可携带式腹膜透析(手动输送透析液)。 • 我们对全自动腹膜透析相比持续性可携带式腹膜透析在肾衰竭患者中的益处或危害尚不确定。我们仅发现了两项研究,共纳入131名患者。 • 需要更大规模且设计良好的研究来确定全自动腹膜透析相较于持续性可携带式腹膜透析的潜在益处。未来的研究应关注重要的患者结局,例如生活质量以及患者参与正常日常生活的能力,包括工作、学习、娱乐和社交活动。 什么是腹膜透析? 肾衰竭是指一个人的肾脏功能不足以维持生命的情况。需要以透析或移植的肾脏替代治疗来维持生命。透析旨在从肾衰竭患者体内清除溶质、毒素和液体,以模拟天然肾脏的功能。腹膜透析是一种利用腹腔内的膜 - 称为腹膜 - 来清除血液中的废物的透析方式。此透析通常在家中进行,甚至可以在睡眠时完成。在腹膜透析过程中,一种称为透析液的液体会通过手术植入的管路进入腹腔。当透析液流入腹腔后,会停留1到6个小时,通过吸收废物和...